4
Changes in Ownership
Rapport Therapeutics, Inc. Filed Acc 0001193125-26-015350
Chief Scientific Officer sold 8,500 shares at an average $26.84 ($228,132)
- Traded under a Rule 10b5-1 plan
From the SEC's structured data for this filing
Trades in this filing
| Insider | Date | Transaction | Shares | Price | Value | Owned after | D/I |
|---|---|---|---|---|---|---|---|
| Bredt David Chief Scientific Officer | 2026-01-15 | Sale 10b5-1 | −8,300 | $26.83 | $222,652 | 395,775 | D |
| Bredt David Chief Scientific Officer | 2026-01-15 | Sale 10b5-1 | −200 | $27.40 | $5,480 | 395,575 | D |
| Open-market sales · 8,500 sh · avg $26.84 · $228,132 | |||||||
Loading xslF345X05/ownership.xml…